KR102206432B1 - 신규 제약 조성물 - Google Patents

신규 제약 조성물 Download PDF

Info

Publication number
KR102206432B1
KR102206432B1 KR1020157016931A KR20157016931A KR102206432B1 KR 102206432 B1 KR102206432 B1 KR 102206432B1 KR 1020157016931 A KR1020157016931 A KR 1020157016931A KR 20157016931 A KR20157016931 A KR 20157016931A KR 102206432 B1 KR102206432 B1 KR 102206432B1
Authority
KR
South Korea
Prior art keywords
drug
powder blend
suitably
direct powder
blend formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157016931A
Other languages
English (en)
Korean (ko)
Other versions
KR20150091352A (ko
Inventor
고제트 캠벨
프란시스코 엔리케즈
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102206432(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20150091352A publication Critical patent/KR20150091352A/ko
Application granted granted Critical
Publication of KR102206432B1 publication Critical patent/KR102206432B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
KR1020157016931A 2012-11-30 2013-11-26 신규 제약 조성물 Active KR102206432B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731597P 2012-11-30 2012-11-30
US61/731,597 2012-11-30
PCT/US2013/071816 WO2014085371A1 (en) 2012-11-30 2013-11-26 Novel pharmaceutical composition

Publications (2)

Publication Number Publication Date
KR20150091352A KR20150091352A (ko) 2015-08-10
KR102206432B1 true KR102206432B1 (ko) 2021-01-22

Family

ID=50828398

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157016931A Active KR102206432B1 (ko) 2012-11-30 2013-11-26 신규 제약 조성물

Country Status (28)

Country Link
US (2) US20150328320A1 (enExample)
EP (2) EP2925299B1 (enExample)
JP (1) JP6232443B2 (enExample)
KR (1) KR102206432B1 (enExample)
CN (2) CN107970214A (enExample)
AR (1) AR093648A1 (enExample)
AU (1) AU2013352369B2 (enExample)
BR (1) BR112015012111A8 (enExample)
CA (1) CA2891346A1 (enExample)
CL (1) CL2015001459A1 (enExample)
EA (2) EA028246B1 (enExample)
ES (1) ES2686730T3 (enExample)
IL (3) IL300664A (enExample)
IN (1) IN2015DN04094A (enExample)
MA (1) MA38121A1 (enExample)
MX (1) MX2015006867A (enExample)
MY (1) MY170427A (enExample)
NZ (1) NZ628395A (enExample)
PE (1) PE20151024A1 (enExample)
PH (1) PH12015501168A1 (enExample)
PL (1) PL2925299T3 (enExample)
PT (1) PT2925299T (enExample)
SG (1) SG11201503688SA (enExample)
TN (1) TN2015000198A1 (enExample)
TW (2) TW201831187A (enExample)
UY (1) UY35157A (enExample)
WO (1) WO2014085371A1 (enExample)
ZA (1) ZA201503346B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
US20200178569A1 (en) * 2016-04-29 2020-06-11 Alvin Kershman Method of Coating an Edible Thermoplastic Pet Chew
TW201818936A (zh) 2016-11-25 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種吡啶酮類衍生物醫藥組成物及其製備方法
KR102230721B1 (ko) * 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
JP2022554148A (ja) * 2019-10-22 2022-12-28 ケミストリーアールエックス 表皮及び真皮の過形成を治療するための方法
AU2022414970A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins
KR20250008895A (ko) * 2022-05-12 2025-01-16 주식회사 지뉴브 안정한 액상 제약 제제
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062743A1 (en) 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
WO2012101238A1 (en) 2011-01-27 2012-08-02 Boehringer Ingelheim International Gmbh New pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US20120219522A1 (en) 2011-02-28 2012-08-30 Dr. Ning XI Substituted quinoline compounds and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
RU2364596C2 (ru) * 2004-06-11 2009-08-20 Джапан Тобакко Инк. ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ
ES2408216T3 (es) * 2004-12-07 2013-06-19 Onyx Therapeutics, Inc. Composición para la inhibición del proteasoma
CN1872055A (zh) * 2005-06-01 2006-12-06 李�杰 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法
EP2581078B1 (en) * 2005-10-26 2014-12-10 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20080176946A1 (en) * 2007-01-16 2008-07-24 Bipar Sciences, Inc. Formulations for cancer treatment
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN101352419B (zh) * 2007-07-26 2010-08-11 天津药物研究院 一种醋溴茶碱无糖型颗粒剂及其制备方法
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
RS65800B1 (sr) * 2009-10-16 2024-08-30 Novartis Ag Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
AU2012238589B2 (en) * 2011-04-07 2017-02-16 Bayer Intellectual Property Gmbh Imidazopyridazines as Akt kinase inhibitors
CN102600132B (zh) * 2012-03-13 2014-05-14 齐鲁制药有限公司 一种含氨磺必利的口服制剂
CN102626394A (zh) * 2012-03-15 2012-08-08 合肥科大生物技术有限公司 一种精氨酸布洛芬颗粒剂及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012062743A1 (en) 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
WO2012101238A1 (en) 2011-01-27 2012-08-02 Boehringer Ingelheim International Gmbh New pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US20120219522A1 (en) 2011-02-28 2012-08-30 Dr. Ning XI Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
EA201791411A1 (ru) 2018-03-30
CL2015001459A1 (es) 2015-12-18
BR112015012111A2 (pt) 2017-07-11
JP2016501874A (ja) 2016-01-21
SG11201503688SA (en) 2015-06-29
AR093648A1 (es) 2015-06-17
EP2925299A1 (en) 2015-10-07
EA028246B1 (ru) 2017-10-31
NZ628395A (en) 2016-10-28
MA38121A1 (fr) 2016-10-31
EP3400933A1 (en) 2018-11-14
AU2013352369B2 (en) 2016-07-28
CN104902876B (zh) 2018-01-19
TN2015000198A1 (en) 2016-10-03
TW201434468A (zh) 2014-09-16
UY35157A (es) 2014-06-30
PH12015501168A1 (en) 2015-08-10
BR112015012111A8 (pt) 2018-01-23
TW201831187A (zh) 2018-09-01
IL238971A0 (en) 2015-07-30
CN104902876A (zh) 2015-09-09
ES2686730T3 (es) 2018-10-19
IL266415A (en) 2019-06-30
IL300664A (en) 2023-04-01
WO2014085371A1 (en) 2014-06-05
MX2015006867A (es) 2015-10-05
MY170427A (en) 2019-07-31
IL266415B2 (en) 2024-03-01
US20170189408A1 (en) 2017-07-06
EA201591047A1 (ru) 2015-11-30
KR20150091352A (ko) 2015-08-10
US20150328320A1 (en) 2015-11-19
HK1209047A1 (en) 2016-03-24
IL238971B (en) 2019-05-30
IN2015DN04094A (enExample) 2015-10-09
JP6232443B2 (ja) 2017-11-15
CN107970214A (zh) 2018-05-01
AU2013352369A1 (en) 2015-05-28
EP2925299A4 (en) 2016-06-29
CA2891346A1 (en) 2014-06-05
PE20151024A1 (es) 2015-07-27
ZA201503346B (en) 2016-01-27
IL266415B1 (en) 2023-11-01
EP2925299B1 (en) 2018-06-06
PT2925299T (pt) 2018-10-16
PL2925299T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
KR102206432B1 (ko) 신규 제약 조성물
CN103998041B (zh) 药物组合物
AU2025242246A1 (en) Novel pharmaceutical composition
HK1259834A1 (en) Novel pharmaceutical trametinib composition
RU2779429C2 (ru) Новая фармацевтическая композиция
CN104902896A (zh) 组合
HK1209047B (en) Novel pharmaceutical composition

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150625

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181029

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200506

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20200914

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210106

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210118

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210118

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241230

Start annual number: 5

End annual number: 5